Serum NT‑proBNP and TUG1 as novel biomarkers for elderly hypertensive patients with heart failure with preserved ejection fraction

Zhang,Shuang; Jin,Rize; Li,Bi

doi:10.3892/etm.2021.9874

Serum NT‑proBNP and TUG1 as novel biomarkers for elderly hypertensive patients with heart failure with preserved ejection fraction

Authors:
- Shuang Zhang
- Rize Jin
- Bi Li
View Affiliations

Affiliations: Ultrasonic Department, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning 121000, P.R. China
Published online on: March 1, 2021 https://doi.org/10.3892/etm.2021.9874
Article Number: 446
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Patients with heart failure with preserved ejection fraction (HFPEF) account for ~50% of all cases of heart failure and their clinical prognosis is poor. The present study attempted to investigate the diagnostic value of circulating long non‑coding RNA taurine upregulated gene 1 (TUG1) for HFPEF in subjects with hypertension. Between January 2017 and January 2019, 80 aged/elderly hypertensive patients with or without HFPEF were recruited for the present study. The concentration of N‑terminal pro‑brain natriuretic peptide (NT‑proBNP) in the serum was measured using ELISA and TUG1 expression levels were determined using reverse transcription‑quantitative PCR. Echocardiography was used for the determination of cardiac function. The results indicated that the levels of NT‑proBNP and TUG1 were increased in the serum of hypertensive patients with HFPEF. Pearson analysis demonstrated that NT‑proBNP and TUG1 were positively correlated with the left atrial diameter and negatively correlated with the ratio of the peak flow velocity in the early diastolic phase to the peak flow velocity in the late diastolic phase. In addition, a positive correlation was confirmed between TUG1 and NT‑proBNP levels. Receiver operating characteristic curve analysis demonstrated that TUG1 and NT‑proBNP were useful biomarkers for the diagnosis of HFPEF. In conclusion, it was observed that NT‑proBNP and TUG1 were increased in the serum of hypertensive patients with HFPEF. Furthermore, TUG1 and NT‑proBNP were indicated to be useful plasma biomarkers for the diagnosis of HFPEF.

View Figures

View References

1	Savarese G and Lund LH: Global public health burden of heart failure. Card Fail Rev. 3:7–11. 2017.PubMed/NCBI View Article : Google Scholar
2	Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Das SR, et al: Heart disease and stroke statistics-2019 update: A report from the american heart association. Circulation. 139:e556–e528. 2019.PubMed/NCBI View Article : Google Scholar
3	Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, et al: 2013 ACCF/AHA guideline for the management of heart failure: A report of the American college of cardiology foundation/American heart association task force on practice guidelines. J Am Coll Cardiol. 62:e147–e239. 2013.PubMed/NCBI View Article : Google Scholar
4	Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL and Redfield MM: Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 355:251–259. 2006.PubMed/NCBI View Article : Google Scholar
5	Paul B, Soon KH, Dunne J and De Pasquale CG: Diagnostic and prognostic significance of plasma N-terminal-pro-brain natriuretic peptide in decompensated heart failure with preserved ejection fraction. Heart Lung Circ. 17:497–501. 2008.PubMed/NCBI View Article : Google Scholar
6	Geisler S and Coller J: RNA in unexpected places: Long non-coding RNA functions in diverse cellular contexts. Nat Rev Mol Cell Biol. 14:699–712. 2013.PubMed/NCBI View Article : Google Scholar
7	Mattick JS and Rinn JL: Discovery and annotation of long noncoding RNAs. Nat Struct Mol Biol. 22:5–7. 2015.PubMed/NCBI View Article : Google Scholar
8	Shi Q and Yang X: Circulating MicroRNA and long noncoding RNA as biomarkers of cardiovascular diseases. J Cell Physiol. 231:751–755. 2016.PubMed/NCBI View Article : Google Scholar
9	Kumarswamy R, Bauters C, Volkmann I, Maury F, Fetisch J, Holzmann A, Lemesle G, de Groote P, Pinet F and Thum T: Circulating long noncoding RNA, LIPCAR, predicts survival in patients with heart failure. Circ Res. 114:1569–1575. 2014.PubMed/NCBI View Article : Google Scholar
10	Gao L, Liu Y, Guo S, Yao R, Wu L, Xiao L, Wang Z, Liu Y and Zhang Y: Circulating long noncoding RNA HOTAIR is an essential mediator of acute myocardial infarction. Cell Physiol Biochem. 44:1497–1508. 2017.PubMed/NCBI View Article : Google Scholar
11	Wang F, Su X, Liu C, Wu M and Li B: Prognostic value of plasma long noncoding RNA ANRIL for in-stent restenosis. Med Sci Monit. 23:4733–4739. 2017.PubMed/NCBI View Article : Google Scholar
12	Young TL, Matsuda T and Cepko CL: The noncoding RNA taurine upregulated gene 1 is required for differentiation of the murine retina. Curr Biol. 15:501–512. 2005.PubMed/NCBI View Article : Google Scholar
13	Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, et al: 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 37:2129–2200. 2016.PubMed/NCBI View Article : Google Scholar
14	Elasfar A: Correlation between plasma N-terminal pro-brain natriuretic peptide levels and changes in New York Heart Association functional class, left atrial size, left ventricular size and function after mitral and/or aortic valve replacement. Ann Saudi Med. 32:469–472. 2012.PubMed/NCBI View Article : Google Scholar
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
16	Bhargava S, Ali A, Manocha A, Kankra M, Das S and Srivastava LM: Homocysteine in occlusive vascular disease: A risk marker or risk factor. Indian J Biochem Biophys. 49:414–420. 2012.PubMed/NCBI
17	Di Palo KE and Barone NJ: Hypertension and heart failure: Prevention, targets, and treatment. Heart Fail Clin. 16:99–106. 2020.PubMed/NCBI View Article : Google Scholar
18	Fitzgibbons TP, Meyer TE and Aurigemma GP: Mortality in diastolic heart failure: An update. Cardiol Rev. 17:51–55. 2009.PubMed/NCBI View Article : Google Scholar
19	Negi SI, Jeong EM, Shukrullah I, Raicu M and Dudley SC Jr: Association of low plasma adiponectin with early diastolic dysfunction. Congest Heart Fail. 18:187–191. 2012.PubMed/NCBI View Article : Google Scholar
20	Poss J, Link A and Bohm M: Acute and chronic heart failure in light of the new ESC guidelines. Herz. 38:812–820. 2013.PubMed/NCBI View Article : Google Scholar : (In German).
21	Zou X, Wang J, Tang L and Wen Q: LncRNA TUG1 contributes to cardiac hypertrophy via regulating miR-29b-3p. In Vitro Cell Dev Biol Anim. 55:482–490. 2019.PubMed/NCBI View Article : Google Scholar
22	Su Q, Liu Y, Lv XW, Dai RX, Yang XH and Kong BH: LncRNA TUG1 mediates ischemic myocardial injury by targeting miR-132-3p/HDAC3 axis. Am J Physiol Heart Circ Physiol. 318:H332–H344. 2020.PubMed/NCBI View Article : Google Scholar
23	Li FP, Lin DQ and Gao LY: LncRNA TUG1 promotes proliferation of vascular smooth muscle cell and atherosclerosis through regulating miRNA-21/PTEN axis. Eur Rev Med Pharmacol Sci. 22:7439–7447. 2018.PubMed/NCBI View Article : Google Scholar